The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16507 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Srinivas Kamath und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmaceutical Innovation (CPI), UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Lurasidone Hydrochloride, Olanzapine, Gastrointestinal Microbiome, Antipsychotic Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hospital Research Foundation.
Abstract (Originalsprache)
Background and Purpose Antipsychotics such as olanzapine are associated with significant metabolic dysfunction, attributed to gut microbiome dysbiosis. A recent notion that most psychotropics are detrimental to the gut microbiome has arisen from consistent findings of metabolic adverse effects. However, unlike olanzapine, the metabolic effects of lurasidone are conflicting. Thus, this study investigates the contrasting effects of olanzapine and lurasidone on the gut microbiome to explore the hypothesis of ‘gut neutrality’ for lurasidone exposure. Experimental Approach Using Sprague–Dawley rats, the effects of olanzapine and lurasidone on the gut microbiome were explored. Faecal and blood samples were collected weekly over a 21‐day period to analyse changes to the gut microbiome and related metabolic markers. Key Results Lurasidone triggered no significant weight gain or metabolic alterations, instead positively modulating the gut microbiome through increases in mean operational taxonomical units (OTUs) and alpha diversity. This novel finding suggests an underlying mechanism for lurasidone's metabolic inertia. In contrast, olanzapine triggered a statistically significant decrease in mean OTUs, substantial compositional variation and a depletion in short‐chain fatty acid abundance. Microbiome depletion correlated with metabolic dysfunction, producing a 30% increase in weight gain, increased pro‐inflammatory cytokine expression, and increased blood glycaemic and triglyceride levels. Conclusion and Implications Our results challenge the notion that all antipsychotics disrupt the gut microbiome similarly and highlights the potential benefits of gut‐neutral antipsychotics, such as lurasidone, in managing metabolic side effects. Further research is warranted to validate these findings in humans to guide personalised pharmacological treatment regimens for schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Pharmaceutical Innovation (CPI), UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
ORCID-Profile: Paul Joyce
Förderung
- Hospital Research Foundation
Zitieren
APA
Kamath, S., Hunter, A., Collins, K., Wignall, A., & Joyce, P. (2024). The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats. British Journal of Pharmacology. https://doi.org/10.1111/bph.16507
Vancouver
Kamath S, Hunter A, Collins K, Wignall A, Joyce P. The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats. British Journal of Pharmacology. 2024. doi:10.1111/bph.16507
BibTeX
@article{Kamath2024,
author = {Kamath, Srinivas and Hunter, Alexander and Collins, Kate and Wignall, Anthony and Joyce, Paul},
title = {The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16507}
}
EUVIMED